Thursday, 15 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 4, 2026

Medallion Financial Corp. Exposes ZimCal’s Latest Campaign of Distortion and the Risks of Electing Its Unqualified Nominees

View original at globenewswire.com
Medallion Financial Corp…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • One former employee's four-year-old lawsuit against several defendants that has not proceeded beyond the pleadings stage is hardly material information

    60% confidence
  • Medallion invested enormous time in dozens of meetings and correspondence with Hodges and always engaged in good faith; in late 2023 the Company offered to purchase his trust preferred securities at a fair price, which he rejected, demanding a premium

    60% confidence
  • Q1 results reflect strong loan growth requiring upfront CECL reserves (the 'growth penalty'); net income over five years totals $266 million, book value per share rose 53% since 2021, and net interest income grew at a 14.1% CAGR since 2021

    60% confidence
  • The Board of Directors unanimously concluded that the ZimCal nominees are materially unqualified to serve on the board of a regulated consumer lending institution and their election would introduce regulatory risk and operational disruption

    60% confidence
  • The SBA matter was a technical issue related to SBA rules and not a financial default; it did not arise from criticism of credit performance or concerns about meeting financial obligations, and the Company has received positive SBA feedback on the cure

    60% confidence
  • The Board has not held management accountable, citing director ages and tenure

    60% confidence
  • ZimCal's goal across three consecutive proxy contests is a debt buyout at above-market price with misaligned incentives, and its campaign contains distortions about key issues

    60% confidence
  • Medallion's total shareholder return since the transformation is 452% and has outperformed its peer group over 1-, 3-, and 5-year periods based on the true unaffected date; Hodges extends the measurement period to May 1, 2026 to manufacture a negative comparison

    60% confidence
  • ZimCal has engaged with Medallion over 50 times and been ignored or dismissed nearly every time

    60% confidence
  • Kelly allegedly asserted sole authority over the company's numbers regardless of accounting objections

    60% confidence
  • Medallion's total shareholder return is the lowest in its peer group

    60% confidence
  • Medallion's performance has been declining

    60% confidence
  • The Company would face a proxy contest 'every year' if it refused to buy out his debt on his terms

    60% confidence
  • Medallion has demonstrated consistent execution across the company's business lines

    60% confidence
  • Eric Kelly diverted customer revenue for personal benefit, misappropriated over 10% of customer prepayments, committed tax fraud by misrepresenting inventory risk, and terminated the CFO within two hours of a whistleblower complaint

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com